Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 28, 2020 05:30 ET | Source: Opthea Limited

Opthea to Host Wet AMD and DME Key Opinion Leader Symposium on August 5, 2020 (EDT)

MELBOURNE, Australia, July 28, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
July 27, 2020 05:30 ET | Source: Opthea Limited

Opthea Reports New Data of OPT-302 in Diabetic Macular Edema at the 2020 Annual Meeting of the American Society of Retina Specialists

MELBOURNE, Australia, July 27, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
July 23, 2020 05:30 ET | Source: Opthea Limited

Opthea Clinical Data of OPT-302 in Diabetic Macular Edema to be Presented at American Society of Retina Specialists 2020 Annual Meeting

MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive...
June 09, 2020 19:23 ET | Source: Opthea Limited

Opthea Reports Positive Phase 2a Trial Results of OPT-302 in Diabetic Macular Edema

Primary endpoint of response with OPT-302 + Eylea® (aflibercept) achieved: 52.8% of refractory DME patients gained ≥ 5 letters of visual acuity at week 12 following OPT-302 combination therapy ...
June 08, 2020 20:37 ET | Source: Opthea Limited

Opthea to Host Investor Teleconference

MELBOURNE, Australia, June 08, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) will host a conference call to discuss the results of the Company’s Phase 2a clinical trial evaluating the safety and...
March 30, 2020 05:30 ET | Source: Opthea Limited

Opthea Completes Patient Dosing in Phase 2a DME Trial

MELBOURNE, Australia, March 30, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has completed...
February 18, 2020 05:30 ET | Source: Opthea Limited

Opthea to Present at the 9th Annual SVB Leerink Global Healthcare Conference

MELBOURNE, Australia, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, today...
January 07, 2020 05:30 ET | Source: Opthea Limited

Opthea Completes Recruitment in Phase 2a Clinical Trial of OPT-302 for Diabetic Macular Edema

MELBOURNE, Australia, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has completed...
October 14, 2019 05:30 ET | Source: Opthea Limited

Opthea Presents Additional Data from OPT-302 Phase 2b Wet AMD Trial at the Ophthalmology Innovation Summit in San Francisco

MELBOURNE, Australia, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases,...
October 03, 2019 05:30 ET | Source: Opthea Limited

Opthea to Present at the Ophthalmology Innovation Summit in San Francisco

MELBOURNE, Australia, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases,...